New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

The U.S. Food and Drug Administration approved Genentech’s Vabysmo (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

2

U.S. orders 100 million additional COVID-19 tests to give out

The United States government procured more than 100 million additional COVID-19 tests from testmaker iHealth Lab Inc. as part of the White House’s plan to distribute 500 million free at-home tests across the country, the Department of Defense said Jan. 28.

3

The Pandemic Has Aggravated the Opioid Crisis – Is Biden’s Plan Enough to Combat It?

The pandemic has undoubtedly altered the way of life for all Americans, but it has also shed light into the bleak statistics that are showing the opioid crisis is even worse than ever before. For the first time in history, the Centers for Disease Control and Prevention (CDC) reported that nearly 100,000 Americans died from drug overdoses over a 12-month period ending in March 2021, which was a little more than a 30 percent increase from the previous year.

4

Taysha’s Promising Gene Therapy Results Marred by Patient’s Death

Shares of Taysha Gene Therapies were down more than 10 percent after a patient’s death marred positive interim data for the company’s experimental gene therapy treatment for Sandhoff and Tay-Sachs diseases, which are two forms of GM2 gangliosidosis.

5

Don’t Count Out Omicron Sibling BA.2, and More COVID-19 News

The prevailing theory about the Omicron variant is that it is going to rip through the population quickly and possibly burn out, marking the downside of the COVID-19 pandemic. But researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark, just as the first Omicron wave subsided.

6

Eli Lilly says FDA could deny expanded use of arthritis drug for eczema

Eli Lilly said on Jan. 28 the company expects the U.S. Food and Drug Administration to decline the approval of expanded use of the rheumatoid arthritis drug Olumiant as a treatment for adults with moderate-to-severe eczema.